Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS)
Go back to Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS)| ARROWHEAD RESEARCH (NASDAQ: ARWR) | Delayed: 81.57 +1.67 (2.09%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $79.90 | 52 Week High | $8.22 | |||
| Open | $80.72 | 52 Week Low | $3.07 | |||
| Day High | $81.99 | P/E | N/A | |||
| Day Low | $80.68 | EPS | $-1.30 | |||
| Volume | 31,637 | |||||
